In an innovative development, UK-based startup BlueSkeye AI is leading the use of artificial intelligence (AI) to revolutionize mental health diagnoses, employing facial tracking technology. In 2019, Professor Michel Valstar, Dr Anthony Brown, and Timur Almaev started a research project at the University of Nottingham. Now, the company has grown into a full-fledged startup, and the goal is to improve how to diagnose mental health conditions.
BlueSkeye AI is testing its unique technology in the UK to determine its ability to assess emotions and mental health in pregnant individuals. The goal is to revolutionize mental healthcare by using AI to identify and track conditions like perinatal depression.
Dr. Anthony Brown, co-founder of BlueSkeye AI, discussed the company’s journey from a small university team to a successful startup. The initial research at the University of Nottingham, funded by the university, showed how AI could identify changes in human behavior linked to medical conditions. Over time, their focus narrowed to detecting depression and, specifically, perinatal depression.
Two years ago, BlueSkeye AI introduced Avocado, a smartphone app for monitoring expectant mothers’ emotional and mental well-being. Many people have used the app—over 200,000 so far, and more are joining. BlueSkeye AI has expanded beyond maternal health, incorporating an automotive component. This aspect focuses on tracking the concentration and tiredness of drivers in the car to enhance road safety.
BlueSkeye AI is growing quickly, doubling its team in the last year. They secured $4.2 million (£3.4 million) in funding from XTX Ventures. The company is involved in a clinical trial with the National Health Service (NHS) and the University of Nottingham. The goal is to improve software for measuring and supporting maternal mental health.
Dr. Brown said there is a high demand for new ways to get mental healthcare, pointing out how mental health issues affect people and society. BlueSkeye AI aims to make it easier for people to access treatment quickly and improve their lives.
The UK’s conducive environment for AI and tech startups has played a pivotal role in BlueSkeye AI’s success. Dr. Brown cited the country’s well-funded and stable education system, drawing talent from around the world, as a major factor. Additionally, the robust legal frameworks and globally recognized laws in the UK facilitate smooth trading with other countries.
The UK’s conducive environment for AI and tech startups in the UK has been crucial to BlueSkeye AI’s success. Dr. Brown mentioned the well-funded and stable education system, attracting talent globally, as a significant factor. Additionally, the strong legal frameworks and globally recognized laws in the UK make it easier for the company to trade with other countries.
BlueSkeye AI is expanding globally by licensing its software development kits to US and EU companies. The company’s next focus is Japan, which plans to establish new business relationships despite facing regulatory and language challenges.
BlueSkeye AI plans to broaden its applications beyond perinatal health and tackle major medical conditions like dementia and Parkinson’s as part of its ambitious growth. This aligns with the company’s mission to have a global impact in the field of mental healthcare.
With the UK joining the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), BlueSkeye AI is set for international expansion. This move opens doors to a region with a total GDP of $14.9 trillion (£12 trillion). The UK’s advantageous research and development tax breaks and a rich talent pool from top universities support its position as an innovation hub.
In conclusion, BlueSkeye AI shows how AI can significantly impact real-world issues, especially in mental health. As the company enters new markets and broadens its services, it represents the positive outcomes that result from the combination of innovation, education, and supportive regulatory environments.
